-
2023-504441-31-00
7
2022-06-29
gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junct
-
2024-516816-72-00
5
2022-04-27
preeclampsia
-
2022-502802-34-00
5
2022-04-05
Dravet and Lennox-Gastaut Syndromes
-
2024-515743-27-00
5
2022-04-04
Childhood Interstitial Lung Disease
-
2024-514570-43-00
5
2022-01-24
Renal cell carcinoma
-
2023-503571-19-00
5
2022-01-20
Chronic Obstructive Pulmonary Disease (COPD)
-
2024-513561-39-00
3
2021-09-08
long-term female contraception
-
2022-500385-99-00
5
2021-06-03
SARS-CoV II infection (Coronavirus disease)
-
2023-504978-38-00
5
2021-03-16
Moderately to Severely Active Crohn's Disease
-
2023-504977-19-00
5
2021-03-15
Moderately to Severely Active Ulcerative Colitis
-
2023-505273-33-00
5
2021-02-15
"Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial
(NTM
-
2023-505336-34-00
6
2020-10-08
Metastatic solid tumors
-
2023-503600-83-00
5
2020-05-27
Moderate to Severe Plaque Psoriasis
-
2023-505167-36-00
5
2019-08-05
Patients who present late on during their acquisition of the HIV-1
(Hu
-
2024-516067-83-00
7
2019-05-02
Severe sickle cell disease (SCD)
-
2023-508832-68-00
9
2019-03-28
Recurrent or stage IVB cervical cancer
-
2023-509061-20-00
9
2018-11-22
Advanced solid tumors
-
2023-510189-28-00
6
2018-05-15
Rheumatoid Arthritis
-
2024-516783-29-00
6
2018-04-16
Severe allergic and eosinophilic asthma
-
2022-500251-22-00
4
2018-04-12
This study will include all patients having received at least one infu
-
2023-508010-42-00
5
2016-09-14
Homologous recombination deficiency advanced ovarian cancer
-
2024-518931-12-00
4
2014-05-15
Neuroblastoma
-
2023-506487-13-00
5
Hormone receptor-positive, her2-negative advanced/metastatic breast ca
-
2024-513863-21-00
3
Type 2 Diabetes Mellitus